Horizon数位前沿主动型ETF YNOT 深 沪
等待开盘 02-04 09:30:00 美东时间
29.0499
-0.363
-1.23%
华盛通- 最 高29.52
- 今 开29.29
- 成交量 1.68万股
- 最 低 28.71
- 昨 收 29.4131
- 总市值 6071.43万
- 52周最高 30.47
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 25.08
- 委 比 -30.43%
- 总股本 209.00万
- 历史最高 30.47
- 量 比 0.15
- 振 幅 2.75%
- 历史最低 25.08
- 每 手 1
- 风险率 1.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49%
Moderna Reports Five-Year Data Showing mRNA-4157 and Keytruda Cut Melanoma Recurrence Risk by 49% Moderna Inc. and Merck have announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which evaluated adjuvant treatment with intismeran autogene in combination with
01-27 23:57
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC Gilead Sciences Inc. announced the publication of full results from the Phase 3 ASCENT-04/KEYNOTE-D19 clinical trial in The New England Journal of Medicine. The study evaluated the efficacy and sa
01-22 06:00
YNOT Invest In Tech? Horizon's New ETFs Balance Innovation And Risk
Horizon introduces 2 new ETFs, taking total to 9. QGRD aims for Nasdaq-100 exposure with downside protection, while YNOT invests in digital firms.
2025-07-15 04:33
